Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0021390 (
inflammatory bowel disease
)
23,302
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Spontaneous colitis in
CTT
's presents cytological characteristics similar to chronic ulcerative colitis in humans, e.g. inflammatory cell infiltrate and crypt abscesses. To better characterize
CTT
colitis as a potential model for human
inflammatory bowel disease
(
IBD
), inflammatory mediators identified in colonic tissue of human
IBD
patients and/or experimental colitis models were assayed. Inflammatory mediator changes in plasma and colon from tamarins with acute (n = 10) and chronic (n = 10) colitis (by mucosal biopsy) were assayed by RIAs. Similar inflammatory mediators were found in the
CTT
's with acute colitis. In the plasma, PAF and PGE2 levels were lower in acute colitis
CTT
's, no LTB4 was detected, and histamine levels were not different from chronic colitic animals. In the colon, myeloperoxidase and interleukin-1 beta were significantly higher in acute colitis, PGE2 and LTB4 were higher but not significantly, and PAF was not different from chronic
CTT
's. These data suggest that a combination of events are occurring in the pathogenesis of tamarin colitis that involves some of the same mediators that are found in the human disease and in other experimental models. The importance of these findings to human
IBD
remains for further investigation; however, the spontaneous primate model offers an exciting approximation of the disease development and merits further investigation for understanding the pathogenesis of human
IBD
as well as to aid in development of targeted therapeutics.
...
PMID:Inflammatory mediators in cotton-top tamarins (CTT) with acute and chronic colitis. 166 91
The exact pathogenesis of diarrhea-dominant irritable bowel syndrome (IBS) is not known, but the abnormal microbiota of the gastrointestinal tract is considered to be one of the important contributing factors as in other gastrointestinal diseases such as
inflammatory bowel disease
, antibiotic-associated diarrhea, and colorectal cancer as well as systemic diseases. Though diverse trials of probiotics had been continued in the treatment of diarrhea-IBS, only a few proved by randomized clinical trial. To prove the efficacy of
Lactobacillus gasseri
BNR17 isolated from breast milk in patients with diarrhea-IBS, prospective, randomized, placebo controlled clinical trial was done including health related-quality of life analysis, colon transit time, and the changes of fecal microbiota. BNR17 significantly improved the symptoms of diarrhea compared to control group. Health related-QOL analysis showed significant improvement of abdominal pain, distension, disturbed daily life, and mean defecation frequency with BNR17. On comparative
CTT
before and after BNR17, 6 out of 24 subjects showed significant correction of rapid colon transit pattern, while only 2 out of 24 in placebo (
p
<0.01). Upon fecal microbiota analysis, BNR17 significantly increased
B. fecalis
,
E. rectale
,
C. aerofaciens
,
F. prausnitzil
and
B. steroris
. Conclusively,
Lactobacillus gasseri
BNR17 can be a potential probiotics to ameliorate diarrhea-IBS.
...
PMID:A double blind, placebo-controlled, randomized clinical trial that breast milk derived-
Lactobacillus gasseri
BNR17 mitigated diarrhea-dominant irritable bowel syndrome. 2961 May 59